BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16908863)

  • 1. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone.
    Hase H; Ando T; Eldeiry L; Brebene A; Peng Y; Liu L; Amano H; Davies TF; Sun L; Zaidi M; Abe E
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12849-54. PubMed ID: 16908863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.
    Ma R; Morshed S; Latif R; Zaidi M; Davies TF
    Thyroid; 2011 Aug; 21(8):897-906. PubMed ID: 21745106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSH is a negative regulator of skeletal remodeling.
    Abe E; Marians RC; Yu W; Wu XB; Ando T; Li Y; Iqbal J; Eldeiry L; Rajendren G; Blair HC; Davies TF; Zaidi M
    Cell; 2003 Oct; 115(2):151-62. PubMed ID: 14567913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic confirmation for a central role for TNFα in the direct action of thyroid stimulating hormone on the skeleton.
    Sun L; Zhu LL; Lu P; Yuen T; Li J; Ma R; Baliram R; Moonga SS; Liu P; Zallone A; New MI; Davies TF; Zaidi M
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9891-6. PubMed ID: 23716650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence.
    Yamoah K; Brebene A; Baliram R; Inagaki K; Dolios G; Arabi A; Majeed R; Amano H; Wang R; Yanagisawa R; Abe E
    Mol Endocrinol; 2008 May; 22(5):1141-53. PubMed ID: 18218727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling.
    Aitken CJ; Hodge JM; Nishinaka Y; Vaughan T; Yodoi J; Day CJ; Morrison NA; Nicholson GC
    J Bone Miner Res; 2004 Dec; 19(12):2057-64. PubMed ID: 15537450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
    Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
    J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
    Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
    J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.
    Zhang W; Zhang Y; Liu Y; Wang J; Gao L; Yu C; Yan H; Zhao J; Xu J
    J Biomech; 2014 Apr; 47(6):1307-14. PubMed ID: 24629929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A RANKL-inducible gene Znf216 in osteoclast differentiation.
    Hishiya A; Ikeda K; Watanabe K
    J Recept Signal Transduct Res; 2005; 25(3):199-216. PubMed ID: 16194934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.
    Kaneda T; Nojima T; Nakagawa M; Ogasawara A; Kaneko H; Sato T; Mano H; Kumegawa M; Hakeda Y
    J Immunol; 2000 Oct; 165(8):4254-63. PubMed ID: 11035059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
    Bharti AC; Takada Y; Aggarwal BB
    J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
    Ren W; Li XH; Chen BD; Wooley PH
    J Orthop Res; 2004 Jan; 22(1):21-9. PubMed ID: 14656655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism.
    Bassett JH; Williams AJ; Murphy E; Boyde A; Howell PG; Swinhoe R; Archanco M; Flamant F; Samarut J; Costagliola S; Vassart G; Weiss RE; Refetoff S; Williams GR
    Mol Endocrinol; 2008 Feb; 22(2):501-12. PubMed ID: 17932107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.